Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trialHiddo J.L. Heerspink, Chris Vercammen, Hans‐Henrik Parving et al.|The Lancet|2019Cited by 609
Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies ConferenceIain C. Macdougall, Elena Zakharova, Yusuke Tsukamoto et al.|Kidney International|2016Cited by 474
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trialMarkus P. Schlaich, Thomas Guldager Lauridsen, M Bellet et al.|The Lancet|2022Cited by 223
Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant HypertensionManish Saxena, Lisa Usdan, Luke J. Laffin et al.|JAMA|2025Cited by 65